Charles Schwab’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.78M | Buy |
283,403
+41,480
| +17% | +$554K | ﹤0.01% | 2448 |
|
|
2025
Q1 | $2.47M | Sell |
241,923
-37,759
| -14% | -$385K | ﹤0.01% | 2545 |
|
|
2024
Q4 | $4.43M | Buy |
279,682
+19,562
| +8% | +$310K | ﹤0.01% | 2386 |
|
|
2024
Q3 | $15.1M | Buy |
260,120
+32,492
| +14% | +$1.89M | ﹤0.01% | 1842 |
|
|
2024
Q2 | $10.4M | Buy |
227,628
+19,870
| +10% | +$908K | ﹤0.01% | 2031 |
|
|
2024
Q1 | $13.8M | Buy |
207,758
+26,180
| +14% | +$1.73M | ﹤0.01% | 1820 |
|
|
2023
Q4 | $7.22M | Buy |
181,578
+4,625
| +3% | +$184K | ﹤0.01% | 2156 |
|
|
2023
Q3 | $5.64M | Buy |
176,953
+29,168
| +20% | +$930K | ﹤0.01% | 2195 |
|
|
2023
Q2 | $5.94M | Buy |
147,785
+15,017
| +11% | +$603K | ﹤0.01% | 2166 |
|
|
2023
Q1 | $5.67M | Sell |
132,768
-584
| -0.4% | -$24.9K | ﹤0.01% | 2142 |
|
|
2022
Q4 | $6.4M | Buy |
133,352
+11,236
| +9% | +$540K | ﹤0.01% | 2080 |
|
|
2022
Q3 | $4.6M | Buy |
122,116
+19,941
| +20% | +$750K | ﹤0.01% | 2256 |
|
|
2022
Q2 | $2.82M | Buy |
102,175
+1,435
| +1% | +$39.7K | ﹤0.01% | 2442 |
|
|
2022
Q1 | $5.48M | Buy |
100,740
+2,404
| +2% | +$131K | ﹤0.01% | 2232 |
|
|
2021
Q4 | $5.75M | Sell |
98,336
-208
| -0.2% | -$12.2K | ﹤0.01% | 2279 |
|
|
2021
Q3 | $3.9M | Buy |
98,544
+19,960
| +25% | +$790K | ﹤0.01% | 2480 |
|
|
2021
Q2 | $3.34M | Buy |
78,584
+20,274
| +35% | +$861K | ﹤0.01% | 2549 |
|
|
2021
Q1 | $3.59M | Buy |
58,310
+2,577
| +5% | +$159K | ﹤0.01% | 2452 |
|
|
2020
Q4 | $3.93M | Buy |
55,733
+11,884
| +27% | +$838K | ﹤0.01% | 2337 |
|
|
2020
Q3 | $1.69M | Buy |
43,849
+442
| +1% | +$17.1K | ﹤0.01% | 2548 |
|
|
2020
Q2 | $1.63M | Buy |
+43,407
| New | +$1.63M | ﹤0.01% | 2485 |
|